IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v5y2014i1d10.1038_ncomms4901.html
   My bibliography  Save this article

Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors

Author

Listed:
  • Anna A. Marusiak

    (Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester)

  • Zoe C. Edwards

    (Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester)

  • Willy Hugo

    (Jonsson Comprehensive Cancer Center and the University of California)

  • Eleanor W. Trotter

    (Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester)

  • Maria R. Girotti

    (Molecular Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester)

  • Natalie L. Stephenson

    (Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester)

  • Xiangju Kong

    (Jonsson Comprehensive Cancer Center and the University of California)

  • Michael G. Gartside

    (Oncogenomics Research Group, QIMR Berghofer Medical Research Institute)

  • Shameem Fawdar

    (Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester)

  • Andrew Hudson

    (Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester)

  • Wolfgang Breitwieser

    (Cell Regulation Group, Cancer Research UK Manchester Institute, The University of Manchester)

  • Nicholas K. Hayward

    (Oncogenomics Research Group, QIMR Berghofer Medical Research Institute)

  • Richard Marais

    (Molecular Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester)

  • Roger S. Lo

    (Jonsson Comprehensive Cancer Center and the University of California)

  • John Brognard

    (Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester)

Abstract

RAF inhibitor therapy yields significant reductions in tumour burden in the majority of V600E-positive melanoma patients; however, resistance occurs within 2–18 months. Here we demonstrate that the mixed lineage kinases (MLK1–4) are MEK kinases that reactivate the MEK/ERK pathway in the presence of RAF inhibitors. Expression of MLK1–4 mediates resistance to RAF inhibitors and promotes survival in V600E-positive melanoma cell lines. Furthermore, we observe upregulation of the MLKs in 9 of 21 melanoma patients with acquired drug resistance. Consistent with this observation, MLKs promote resistance to RAF inhibitors in mouse models and contribute to acquired resistance in a cell line model. Lastly, we observe that a majority of MLK1 mutations identified in patients are gain-of-function mutations. In summary, our data demonstrate a role for MLKs as direct activators of the MEK/ERK pathway with implications for melanomagenesis and resistance to RAF inhibitors.

Suggested Citation

  • Anna A. Marusiak & Zoe C. Edwards & Willy Hugo & Eleanor W. Trotter & Maria R. Girotti & Natalie L. Stephenson & Xiangju Kong & Michael G. Gartside & Shameem Fawdar & Andrew Hudson & Wolfgang Breitwie, 2014. "Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors," Nature Communications, Nature, vol. 5(1), pages 1-11, September.
    • Handle: RePEc:nat:natcom:v:5:y:2014:i:1:d:10.1038_ncomms4901
    DOI: 10.1038/ncomms4901
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/ncomms4901
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/ncomms4901?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:5:y:2014:i:1:d:10.1038_ncomms4901. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.